Sorafenib extends the survival time of patients with multiple recurrences of hepatocellular carcinoma after liver transplantation

Acta Pharmacologica Sinica

Volumn 31, Issue 12, 2010, Pages 1643-1648

  Tan, Wei Feng ^a   Qiu, Zhi Quan ^a   Yu, Yong ^a   Ran, Rong Zheng ^a   Yi, Bing ^a   Lau, Wan Yee ^a,b   Liu, Chen ^a   Qiu, Ying He ^a   Feng, Fei Ling ^a   Wang, Jing Han ^a   Yan, Pei Ning ^a   Zhang, Bai He ^a   Wu, Meng Chao ^a   Luo, Xiang Ji ^a   Jiang, Xiao Qing ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

Author keywords

hepatocellular carcinoma; molecular targeted therapy; sorafenib; survival analysis; transarterial chemoembolization

Indexed keywords

SORAFENIB;

ADULT; ADVERSE OUTCOME; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL ARTICLE; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; INSOMNIA; KAPLAN MEIER METHOD; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MALE; MOLECULARLY TARGETED THERAPY; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL TIME; TRANSARTERIAL CHEMOEMBOLIZATION; TREATMENT OUTCOME; UNIVARIATE ANALYSIS;

ADULT; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; NEOPLASM RECURRENCE, LOCAL; PYRIDINES; RETROSPECTIVE STUDIES;

EID: 78649952142     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2010.124     Document Type: Article

References (22)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics. CA Cancer J Clin 2005;55:74-108.
2. Yates MS, Kensler TW. Keap1 eye on the target: chemoprevention of liver cancer. Acta Pharmacol Sin 2007;28:1331-42.
3. Sherman M. Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis 2005;25:143-54.
4. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-17.
5. Mi JX, Wang GF, Wang HB, Sun XQ, Ni XY, Zhang XW, et al. Synergisti c antitumoral activity and induction of apoptosis by novel pan Bcl-2 protein s inhibitor apogossypolone with adriamycin in human hepa tocellular carcinoma. Acta Pharmacol Sin 2008;29:1467-77.
6. Llovet JM, Schwartz M, Mazzaferro V. Resection and liver trans plantation for hepatocellular carcinoma. Semin Liver Dis 2005;25:181-200.
7. Pan QW, Zhong SY, Liu BS, Liu J, Cai R, Wang YG, et al. Enhanced sensitivity of hepatocellular carcinoma cells to chemotherapy with a Smac-armed oncolytic adenovirus. Acta Pharmacol Sin 2007;28:1996-2004.
8. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepato logy 2005;42:1208-36.
9. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-17.
10. Bruix J, Boix L, Sala M, Llovet JM. Focus on hepatocellular carcinoma. Cancer Cell 2004;5:215-9.
11. Thomas MB, Zhu AX. Hepatocellular carcinoma: the need for progress. J Clin Oncol 2005;23:2892-9.
12. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003;37:429-42.
13. Lopez PM, Villanueva A, Llovet JM. Systematic review: evidencebased management of hepatocellular carcinoma-an updated analysis of randomized controlled trials. Aliment Pharmacol Ther 2006;23:1535-47.
14. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109.
15. Chang YS, Adnane J, Trail PA, Levy J, Henderson A, Xue D, et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol 2007;59:561-74.
16. Ito Y, Sasaki Y, Horimoto M, Wada S, Tanaka Y, Kasahara A, et al. Activation of mitogen-activated protein kinases/extracellular signalregulated kinases in human hepatocellular carcinoma. Hepatology 1998;27:951-8.
17. Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM. Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 2007;27:55-76.
18. Calvisi DF, Ladu S, Gorden A, Farina M, Conner EA, Lee JS, et al. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 2006;130:1117-28.
19. Semela D, Dufour JF. Angiogenesis and hepatocellular carcinoma. J Hepatol 2004;41:864-80.
20. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006;66:11851-8.
21. Sergio A, Cristofori C, Cardin R, Pivetta G, Ragazzi R, Baldan A, et al. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol 2008;103:914-21
22. Strebel BM, Dufour JF. Combined approach to hepatocellular carcinoma: a new treatment concept for nonresectable disease. Expert Rev Anticancer Ther 2008;8:1743-9.